Lyon, France - January 20, 2026, 18:00 p.m. CET - THX Pharma (Theranexus), an innovative biopharmaceutical company in the treatment of rare neurological diseases, today announces its financial communication agenda for. Each publication will be released after Euronext market closing, unless otherwise specified . These dates are given as an indication, they are likely to be modified if necessary.
Indicative calendar for 2026 financial communication
| Events | Dates | |
| Cash position as at December 31, 2025 | 19 February 2026 | |
| 2025 Annual Results and Cash position as at 31/03/26 | 28 April 2026 | |
| Shareholders' General Meeting | 23 June 2026, 10 am | |
| Cash position as at June 30, 2026 | 9 July 2026 | |
| 2026 Half-Year Results as at June 30, 2026 | 29 September 2026 | |
| Cash position as at September 30, 2026 | 22 October 2026 | |
About THX Pharma
THX Pharma (Theranexus) is a pharmaceutical company specializing in treatments for rare neurological diseases. Its first drug, TX01, is expected to be commercialized soon-particularly in Europe by Exeltis, but also in the United States, Canada, and Australia-for Niemann-Pick type C disease and Gaucher disease. Its second drug, Batten-1, targets the juvenile form of Batten disease and could become the first approved therapy for this condition.
THX Pharma also has an innovative antisense oligonucleotide platform, codeveloped with leading research laboratories, dedicated to rare neurological diseases. THX Pharma, a trade name of Theranexus, is listed on Euronext Growth Paris (FR0013286259 - ALTHX).
For more information:
http://www.theranexus.com
Click and follow us on LinkedIn
Contacts:
THX PHARMA
Christine PLACET
Chief Financial Officer
contact@thxpharma.com
FP2COM
Florence PORTEJOIE
Media Relations
+ 33 (0)6 07 76 82 83
fportejoie@fp2com.fr
Forward-looking statements
This press release contains forward-looking statements relating to THX Pharma (Theranexus) and its activities, including its prospects and product development. Theranexus believes that these forward-looking statements are based on reasonable assumptions. However, forward-looking statements are not guarantees of future performance, as they relate to future events and depend on circumstances that may or may not occur in the future, and on various risks and uncertainties, including those described in the universal registration document filed by the company with the AMF (Autorité des Marchés Financiers) on April 29, 2025, under number D.25-0350, a copy of which is available on the company's website (www.theranexus.com), and on changes in the economic situation.
- SECURITY MASTER Key: ym+alJhvZ2yYnp+fZMiYZ2ZnmZuWyJGZmWnLx2OaZJbKaJ2SxmlobsjGZnJnlW1t
- Check this key: https://www.security-master-key.com.
https://www.actusnews.com/documents_communiques/ACTUS-0-96087-thx_pharma_pr_2026_financial_agenda_vdef.pdf
© Copyright Actusnews Wire
Receive by email the next press releases of the company by registering on www.actusnews.com, it's free
